Autolus Therapeutics Ltd (AUTL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.94 (+1.04%), Market cap $0.43B, 52-week low–high $1.21 ~ $2.68.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple
Financial statements, price targets, institutional (13F) holdings and related news for Autolus Therapeutics Ltd are updated in real time on BlackAll Trade.
Autolus Therapeutics Ltd trades at $1.94 (+1.04%). Real-time quotes and charts are available on BlackAll Trade.
Autolus Therapeutics Ltd has a market cap of about $0.43B.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The compa